Compare Verisign, Inc. (VRSN) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Verisign, Inc. vs GeneDx Holdings Corp — how do they compare? Verisign, Inc. trades at $268.94 (market cap $25.26B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Verisign, Inc. is far larger — about 14× GeneDx Holdings Corp's market cap, and Verisign, Inc. pays a 1.17% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| VRSN | WGS | |
|---|---|---|
Market Cap | $25.26B | $1.80B |
Sector | Technology | Technology |
52-Week High | $310.00 | $167.51 |
52-Week Low | $211.49 | $34.51 |
Enterprise Value | $26.50B | $1.80B |
Dividend Yield | 1.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VeriSign (VRSN) trades at $266.15, down 4.15% over the past day, with a mixed technical outlook showing bullish moving averages but overbought oscillators. The company maintains strong fundamentals with 2025 revenue of $1.66 billion, net income of $825.7 million, and a robust net income margin of 49.96%. Recent Q1 2026 earnings beat expectations with EPS of $2.34, while Q2 2026 results are anticipated. Analyst sentiment is predominantly positive with a 57% buy rating and a consensus price target of $325.25, suggesting significant upside potential.
The outlook for VRSN is cautiously optimistic, driven by its monopoly position in .com and .net domain registrations, consistent cash flow generation, and potential tailwinds from AI-driven domain growth. Key risks include contract renewal uncertainties, competitive pressures, and high valuation multiples. Investors should weigh the stock's premium valuation against its stable revenue streams and growth catalysts from digital expansion.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
